Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

ABSTRACT: Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

PROVIDER: PRJNA624325 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11523540_1.fastq.gz	Fastqsanger.gz
	SRR11523540_2.fastq.gz	Fastqsanger.gz
	SRR11523541_1.fastq.gz	Fastqsanger.gz
	SRR11523541_2.fastq.gz	Fastqsanger.gz
	SRR11523542_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

Project description:Lung cancer is the leading cause of cancer-related deaths world-wide. ~85% of lung carcinomas are non–small cell lung carcinoma (NSCLC). Tumor cell heterogeneity is very poorly defined. However, it is known to be important for tumor response to cancer therapy and cancer agressivenes. We subjected three NSCLC tumors resected from different patients to Drop-seq in order to 1) elucidate the capability of scRNA-seq analysis in identifying different tumor cell populations; and 2) ascertain the clinical value of the genes which distinguish cancer cells from other cells in the tissue. As anticipated, the tissue composition of independently collected samples varied. Despite deficient populations in some samples, both donor and patient samples contributed to the majority of cell populations. However, cancer cells were all patient-specific. These findings emphasize the utility of single cell gene expression data in identification of tumor cell populations. The collected data might be further used for predicting of drugs specific to the biology of activated pathways and patient outcome.

2020-12-19 | GSE148466 | GEO

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

Project description:To identify genes encoding cell surface proteins that are preferentially expressed in NSCLC cells, CD45-CD31-EpCAM+ cells were purified by FACS from either tumor regions or unaffected regions in resected lung tissues from patients with NSCLC, then subjected to RNA sequencing analysis.

2024-08-05 | GSE226773 | GEO

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

2024-08-05 | GSE226772 | GEO

Single cell RNA sequencing analysis of freshly resected PC9 cell line-derived tumor xenografts

Project description:Single cell RNA sequencing analysis of freshly resected PC9 cell line-derived tumor xenografts

| PRJNA672709 | ENA

Transcriptomic analysis of patient-derived resected lung NSCLC cells

Project description:Transcriptomic analysis of patient-derived resected lung NSCLC cells

| PRJNA941787 | ENA

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

Project description:Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

| PRJNA942048 | ENA

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

Project description:Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

| PRJNA942052 | ENA

Gene expression profiles of tumor and paired normal lung tissues from primary non-small cell lung cancer (NSCLC) patients in Taiwan.

2013-05-15 | GSE21933 | GEO

Single cell RNA sequencing analysis of freshly resected PC9 cell line-derived tumor xenografts

Project description:The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. Using PC9 cells, we generated EGFR-mutant lung cancer xenografts to study the differences in response between individual cells and cell populations. We performed treatment of PC9 xenograft tumors with the combination of osimertinib and crizotinib as well as single drugs, followed by Drop-seq. The addition of crizotinib was guided by our previous data in PC9 grown in cell culture that identified an erlotinib-resistant drug population sensitive to crizotinib. The results of the xenograft study show that combination treatment targets specific osimertinib-tolerant cell populations but leaves a subset of the population that is tolerant to the combo. Each cell subpopulation is characterized by specific molecular signatures. The results of our study help to address emerging drug resistance that limits clinical usefulness of targeted strategies, particularly in NSCLC.

2020-12-19 | GSE160244 | GEO

Gene expression profiles of tumor and paired normal lung tissues from primary non-small cell lung cancer (NSCLC) patients in Taiwan.

Project description:Genome-wide expression profiling of NSCLC patients were done using Phalanx Human OneArray chip. The surgically resected tumor tissue and corresponding normal tissue were collected from 21 patients diagnosed with primary NSCLC admitted to Taipei Veterans General Hospital, Taiwan. In this study, we used cDNA microarray to detect gene expression profiling in tumor and corresponding normal samples from 21 NSCLC patients. There were 11 AD patients and 10 SQ patients. The patients consisted of 10 early stage patients (stages I and II) and 11 late stage patients (stages III and IV). Hybridization targets were prepared from total RNA and hybridized according to standard protocol using Phalanx Human OneArray chip (32,050 total features: 30968 human genome probes and 1082 experimental control probes).

2013-05-15 | E-GEOD-21933 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data